Projects In Knowledge, Inc
Highlights of the European Committee for Treatment and Research in Multiple Sclerosis Annual MeetingEpisodes
Episodes of Highlights of the European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Mark All
Search Episodes...
Dr. Lublin discusses new data on other existing MS therapies: interferon beta, natalizumab, mitoxantrone, and fampridine.
Dr. Lublin discusses new data on existing MS therapies: glatiramer acetate and fingolimod, as well as the addition of statins to interferon beta-1a.
Dr. Lublin describes the latest data presented at ECTRIMS on additional emerging MS therapies (firategrast, cladribine, alemtuzumab, daclizumab, laquinimod, BG00012).
Dr. Lublin describes the latest data on some of the emerging MS therapies now in late-stage clinical trials (teriflunomide, ocrelizumab and ofatumumab), presented on ECTRIMS.
In this next section of the podcast, Dr. Bowen looks at the extent to which new data at ECTRIMS answer some important questions about MS testing, neuroregeneration, and cognitive impairment.
Dr. Bowen discusses ECTRIMS presentations on lesser-known components of the immune system that contribute to the disease. He also discusses data on genetic causes of MS.
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us